{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:01:56Z","timestamp":1790402516209,"version":"4.1.0"},"reference-count":0,"publisher":"Komitet Redakcyjno - Wydawniczy Polskiego Towarzystwa Psychiatrycznego","issue":"6","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatr Pol"],"published-print":{"date-parts":[[2025,12,31]]},"abstract":"<jats:p>Wprowadzenie: Olanzapina (OLZ) jest szeroko stosowanym lekiem przeciwpsychotycznym II generacji w schizofrenii i chorobie afektywnej dwubiegunowej typu I (ChAD-I). U m\u0142odzie\u017cy jej u\u017cycie ogranicza profil metaboliczny.\nCel: Przedstawienie mechanizm\u00f3w dzia\u0142ania OLZ oraz ocena jej skuteczno\u015bci i bezpiecze\u0144stwa u nastolatk\u00f3w z rozpoznaniami ze spektrum schizofrenii, z odniesieniem do wytycznych.\nMetody: Przegl\u0105d narracyjny randomizowanych bada\u0144 kontrolowanych (RCT), bada\u0144 otwartych, metaanaliz oraz zalece\u0144 APA, NICE i wytycznych kanadyjskich.\nWyniki: OLZ wykazuje wielokierunkowy antagonizm receptorowy (D\u2082, 5-HT\u2082A\/2C, H\u2081, M\u2081\u2013M\u2085, \u03b1\u2081), zapewniaj\u0105c istotn\u0105 redukcj\u0119 objaw\u00f3w pozytywnych; w RCT u m\u0142odzie\u017cy obserwowano popraw\u0119 w skalach PANSS, BPRS-C i YMRS. Farmakokinetyka jest zbli\u017cona do doros\u0142ych, przy ~27\u201334% wy\u017cszej ekspozycji u nastolatk\u00f3w. Dzia\u0142ania niepo\u017c\u0105dane s\u0105 cz\u0119stsze i silniejsze ni\u017c u doros\u0142ych (przyrost masy cia\u0142a, dyslipidemia, zaburzenia glikemii, hiperprolaktynemia). Wytyczne uznaj\u0105 OLZ za opcj\u0119 w schizofrenii i lek pierwszego rzutu w ostrej manii; kombinacja olanzapina\u2013fluoksetyna rekomendowana jest w depresji dwubiegunowej przez wi\u0119kszo\u015b\u0107, lecz nie przez NICE. Preparat depot (LAI) nie jest dopuszczony &lt;18 r.\u017c.\nWnioski: OLZ jest skuteczna w psychozie i manii u m\u0142odzie\u017cy, lecz obci\u0105\u017cona wysokim ryzykiem metabolicznym. Przy braku przewagi skuteczno\u015bci nad innymi SGA powinna by\u0107 rozwa\u017cana jako lek drugiego rzutu, preferencyjnie w monoterapii, z ostro\u017cn\u0105 titracj\u0105 i \u015bcis\u0142ym monitorowaniem metabolicznym; dowody na wp\u0142yw na objawy negatywne i funkcje poznawcze s\u0105 ograniczone.<\/jats:p>","DOI":"10.12740\/pp\/214532","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T16:50:15Z","timestamp":1767718215000},"page":"1003-1015","source":"Crossref","is-referenced-by-count":1,"title":["Olanzapine in the treatment of schizophrenia in adolescents \u2013 mechanisms of action and therapeutic efficacy."],"prefix":"10.12740","volume":"59","author":[{"given":"Wiktoria","family":"Nowak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Korba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Kinalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kubik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-188X","authenticated-orcid":false,"given":"Anna","family":"Lizo\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0452-295X","authenticated-orcid":false,"given":"Wirginia","family":"Krzy\u015bciak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5036","published-online":{"date-parts":[[2025,12,31]]},"container-title":["Psychiatria Polska"],"original-title":[],"link":[{"URL":"https:\/\/www.psychiatriapolska.pl\/pdf-214532-134064","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.psychiatriapolska.pl\/pdf-214532-134064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T16:50:18Z","timestamp":1767718218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.psychiatriapolska.pl\/Olanzapine-in-the-treatment-of-schizophrenia-in-adolescents-mechanisms-of-action,214532,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"alternative-id":["214532"],"URL":"https:\/\/doi.org\/10.12740\/pp\/214532","relation":{},"ISSN":["0033-2674","2391-5854"],"issn-type":[{"value":"0033-2674","type":"print"},{"value":"2391-5854","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]}}}